CELLECTRA® 2000

DEVICE8 trials

Conditions

COVID-19 DiseaseCoronavirus InfectionHIV-1-infectionHealthy VolunteersLassa FeverRespiratory PapillomatosisSARS-CoV 2Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Phase 1

Therapeutic Vaccination in Treated HIV Disease

CompletedNCT03606213

Steven DeeksHIV-1-infection

Start: 2018-08-01End: 2021-05-17Updated: 2023-05-31

Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

CompletedNCT03805984

Inovio PharmaceuticalsLassa Fever

Start: 2019-05-09End: 2020-10-21Updated: 2020-11-23

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

CompletedNCT03831503

University of PennsylvaniaHealthy Volunteers

Start: 2019-02-07End: 2022-10-03Updated: 2023-12-14

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

CompletedNCT04336410

Inovio PharmaceuticalsCoronavirus Infection

Start: 2020-04-03End: 2022-02-10Updated: 2022-04-15

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

CompletedNCT04398433

Inovio PharmaceuticalsRespiratory Papillomatosis

Start: 2020-10-07End: 2022-12-15Updated: 2026-04-14

Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

CompletedNCT04447781

International Vaccine InstituteCoronavirus Infection, SARS-CoV 2

Start: 2020-07-15End: 2022-05-25Updated: 2022-07-18

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

WithdrawnNCT05430958

Inovio PharmaceuticalsCoronavirus Infection

Start: 2022-10-31End: 2024-03-31Updated: 2022-11-17

Phase 2

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

TerminatedNCT04642638

Inovio PharmaceuticalsCoronavirus Infection, COVID-19 Disease, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Start: 2020-11-30End: 2022-09-13Updated: 2023-12-20

Cancer Immunology Research2026-02-18

Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial

BMC Infectious Diseases2025-05-25

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107

Nature Communications2025-02-1213 citations

Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial

Human Vaccines & Immunotherapeutics2025-01-266 citations

Abstract A005: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways

Cancer Immunology Research2024-10-18

Interim Results of a Phase 1/2 <scp>Open‐Label</scp> Study of <scp>INO</scp>‐3107 for <scp>HPV</scp>‐6 and/or <scp>HPV</scp>‐11‐Associated Recurrent Respiratory Papillomatosis

The Laryngoscope2023-05-1930 citations

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

The Journal of Infectious Diseases2022-01-2459 citations

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

Open Forum Infectious Diseases2021-11-012 citations

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.

2020-12-24202 citations

Understanding COVID-19 Vaccines and Their Development

Journal of Bone and Joint Surgery2020-07-316 citations

Are Genetic Vaccines the Right Weapon against COVID-19?

Molecular Therapy2020-06-0921 citations

Progress and Concept for COVID‐19 Vaccine Development

Biotechnology Journal2020-04-18115 citations

CELLECTRA® 2000

Sponsors

Conditions

Phase 1

Phase 2

Related Papers